| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Regular Articles |
From the Massachusetts Eye and Ear Infirmary,*Harvard Medical School, Boston, Massachusetts; the Department of Adult Oncology,Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts; the Department of Pathology,School of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece; the Endocrine Unit,Evgenidion Hospital, Athens, Greece; and the Department of Molecular Oncology,¶Genentech Incorporated, South San Francisco, California
Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL)/Apo2 ligand selectively kills neoplastic cells, including thyroid carcinoma cells (Mitsiades et al: Thyroid carcinoma cells are resistant to FAS-mediated apoptosis but sensitive to tumor necrosis factor-related apoptosis-inducing ligand. Cancer Res 2000, 60:4122–41299). We investigated the mechanisms regulating Apo2L/TRAIL-induced apoptosis in thyroid carcinoma cells, as well as the impact of insulin-like growth factor (IGF)-1, interferon-
, and TNF-
. We found that the emergence of resistance to Apo2L/TRAIL, after prolonged incubation with this cytokine, was associated with increased levels of FLICE inhibitory protein (FLIP), and was overcome by cycloheximide and bisindolylmaleimide, that specifically down-regulated FLIP expression, as well as by transfection of a FLIP anti-sense oligonucleotide. IGF-1 activated Akt; up-regulated the caspase inhibitors FLIP, cIAP-2, XIAP, and survivin; and attenuated Apo2L/TRAIL-induced apoptosis. This effect was inhibited by the IGF-1 receptor neutralizing antibody aIR3, the PI-3K inhibitor wortmannin, and the heat shock protein-90 chaperone inhibitor geldanamycin. Transfection of constitutively active Akt protected from TRAIL. Conversely, interferon- and TNF- had a sensitizing effect. We conclude that FLIP may negatively regulate Apo2L/TRAIL-induced apoptosis in thyroid carcinomas. Microenvironmental paracrine survival factors, such as IGF-1, up-regulate caspase inhibitors, including FLIP, and protect from Apo2L/TRAIL in a PI-3K/Akt-dependent manner. T helper-1 cytokines and compounds that selectively abrogate the IGF-1 signaling pathway may be helpful adjunct agents in Apo2L/TRAIL-based anti-cancer therapeutic regimens.
This article has been cited by other articles:
 |
|
 |
|
  C. S. Mitsiades, P. Hayden, V. Kotoula, D. W. McMillin, C. McMullan, J. Negri, J. E. Delmore, V. Poulaki, and N. Mitsiades Bcl-2 Overexpression in Thyroid Carcinoma Cells Increases Sensitivity to Bcl-2 Homology 3 Domain Inhibition J. Clin. Endocrinol. Metab., December 1, 2007; 92(12): 4845 - 4852. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. R. Wilson, K. M. McLaughlin, M. McEwan, H. Sakai, K. M.A. Rogers, K. M. Redmond, P. G. Johnston, and D. B. Longley c-FLIP: A Key Regulator of Colorectal Cancer Cell Death Cancer Res., June 15, 2007; 67(12): 5754 - 5762. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Ren, Q. Guan, X. Zhong, B. Gong, Y. Sun, W. Xin, J. Guo, H. Wang, L. Gao, and J. Zhao Phosphatidylinositol 3-kinase/nuclear factor-{kappa}B signaling pathway is involved in the regulation of IGF-I on Fas-associated death domain-like interleukin-1-converting enzyme-inhibitory protein expression in cultured FRTL thyroid cells J. Mol. Endocrinol., June 1, 2007; 38(6): 619 - 625. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Chiappetta, M. Ammirante, A. Basile, A. Rosati, M. Festa, M. Monaco, E. Vuttariello, R. Pasquinelli, C. Arra, M. Zerilli, et al. The Antiapoptotic Protein BAG3 Is Expressed in Thyroid Carcinomas and Modulates Apoptosis Mediated by Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand J. Clin. Endocrinol. Metab., March 1, 2007; 92(3): 1159 - 1163. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. S. Mitsiades, J. Negri, C. McMullan, D. W. McMillin, E. Sozopoulos, G. Fanourakis, G. Voutsinas, S. Tseleni-Balafouta, V. Poulaki, D. Batt, et al. Targeting BRAFV600E in thyroid carcinoma: therapeutic implications Mol. Cancer Ther., March 1, 2007; 6(3): 1070 - 1078. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. S. Bharhani, R. Borojevic, S. Basak, E. Ho, P. Zhou, and K. Croitoru IL-10 protects mouse intestinal epithelial cells from Fas-induced apoptosis via modulating Fas expression and altering caspase-8 and FLIP expression. Am J Physiol Gastrointest Liver Physiol, November 1, 2006; 291(5): G820 - G829. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. S. Mitsiades, V. Poulaki, G. Fanourakis, E. Sozopoulos, D. McMillin, Z. Wen, G. Voutsinas, S. Tseleni-Balafouta, and N. Mitsiades Fas signaling in thyroid carcinomas is diverted from apoptosis to proliferation. Clin. Cancer Res., June 15, 2006; 12(12): 3705 - 3712. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Tirro, M. L. Consoli, M. Massimino, L. Manzella, F. Frasca, L. Sciacca, L. Vicari, G. Stassi, L. Messina, A. Messina, et al. Altered Expression of c-IAP1, Survivin, and Smac Contributes to Chemotherapy Resistance in Thyroid Cancer Cells. Cancer Res., April 15, 2006; 66(8): 4263 - 4272. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Todaro, M. Zerilli, L. Ricci-Vitiani, M. Bini, M. Perez Alea, A. Maria Florena, L. Miceli, G. Condorelli, S. Bonventre, G. Di Gesu, et al. Autocrine Production of Interleukin-4 and Interleukin-10 Is Required for Survival and Growth of Thyroid Cancer Cells Cancer Res., February 1, 2006; 66(3): 1491 - 1499. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Galligan, D. B. Longley, M. McEwan, T. R. Wilson, K. McLaughlin, and P. G. Johnston Chemotherapy and TRAIL-mediated colon cancer cell death: the roles of p53, TRAIL receptors, and c-FLIP Mol. Cancer Ther., December 1, 2005; 4(12): 2026 - 2036. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Kawamura, J. Fukuda, Y. Shimizu, H. Kodama, and T. Tanaka Survivin Contributes to the Anti-Apoptotic Activities of Transforming Growth Factor alpha in Mouse Blastocysts Through Phosphatidylinositol 3'-Kinase Pathway Biol Reprod, December 1, 2005; 73(6): 1094 - 1101. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. S. Mitsiades, V. Poulaki, C. McMullan, J. Negri, G. Fanourakis, A. Goudopoulou, V. M. Richon, P. A. Marks, and N. Mitsiades Novel Histone Deacetylase Inhibitors in the Treatment of Thyroid Cancer Clin. Cancer Res., May 15, 2005; 11(10): 3958 - 3965. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.-E. Kim and S. R. Tannenbaum Insulin Regulates Cleavage of Procaspase-9 via Binding of X Chromosome-Linked Inhibitor of Apoptosis Protein in HT-29 Cells Cancer Res., December 15, 2004; 64(24): 9070 - 9075. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. Wu, H. Zeng, X. Zhang, Y. Zhao, H. Sha, X. Ge, M. Zhang, X. Gao, and Q. Xu Phosphatase of Regenerating Liver-3 Promotes Motility and Metastasis of Mouse Melanoma Cells Am. J. Pathol., June 1, 2004; 164(6): 2039 - 2054. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Fischer-Posovszky, H. Tornqvist, K.-M. Debatin, and M. Wabitsch Inhibition of Death-Receptor Mediated Apoptosis in Human Adipocytes by the Insulin-Like Growth Factor I (IGF-I)/IGF-I Receptor Autocrine Circuit Endocrinology, April 1, 2004; 145(4): 1849 - 1859. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Santiago, M. Galindo, G. Palao, and J. L. Pablos Intracellular Regulation of Fas-Induced Apoptosis in Human Fibroblasts by Extracellular Factors and Cycloheximide J. Immunol., January 1, 2004; 172(1): 560 - 566. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Poulaki, C. S. Mitsiades, C. McMullan, D. Sykoutri, G. Fanourakis, V. Kotoula, S. Tseleni-Balafouta, D. A. Koutras, and N. Mitsiades Regulation of Vascular Endothelial Growth Factor Expression by Insulin-Like Growth Factor I in Thyroid Carcinomas J. Clin. Endocrinol. Metab., November 1, 2003; 88(11): 5392 - 5398. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Greil, G. Anether, K. Johrer, and I. Tinhofer Tracking death dealing by Fas and TRAIL in lymphatic neoplastic disorders: pathways, targets, and therapeutic tools J. Leukoc. Biol., September 1, 2003; 74(3): 311 - 330. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
